Management of ascites due to gastrointestinal malignancy

Annals of Saudi Medicine

Volumn 29, Issue 5, 2009, Pages 369-377

  Saif, Muhammad W ^a   Siddiqui, Imran A P ^a   Sohail, Muhammad A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ALBUMIN; ALPHA2B INTERFERON; AMILORIDE; BATIMASTAT; BUMETANIDE; DORZOLAMIDE; EPLERENONE; ETACRYNIC ACID; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IODINE 131; MANNITOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2G3; OCTREOTIDE; PICIBANIL; PROTEIN; SPIRONOLACTONE; TORASEMIDE; TRIAMTERENE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VATALANIB; VISCUM ALBUM EXTRACT;

ABDOMINAL DISTENSION; ASCITES; ASCITES FLUID ANALYSIS; BONE MARROW SUPPRESSION; BREAST ADENOCARCINOMA; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; COLON ADENOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; CONSTRICTIVE PERICARDITIS; DEHYDRATION; DIAGNOSTIC PROCEDURE; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DRUG MECHANISM; DYSPNEA; ECHOGRAPHY; ENDOCRINE DISEASE; FEVER; GYNECOMASTIA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPOCALCEMIA; HYPOCHLOREMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOVOLEMIA; IMMOBILIZATION; LAPAROSCOPIC SURGERY; LAPAROTOMY; LEG EDEMA; LEUKOCYTE COUNT; LIVER CIRRHOSIS; METABOLIC ACIDOSIS; METABOLIC ALKALOSIS; NAUSEA AND VOMITING; NEPHROTIC SYNDROME; NEUROPATHY; OVARY ADENOCARCINOMA; PANCREAS ADENOCARCINOMA; PARACENTESIS; PERITONEUM CANCER; PERITONEUM VEIN SHUNT; PERITONITIS; PORTAL VEIN BLOOD PRESSURE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SATIETY; SODIUM RESTRICTION; STOMACH ADENOCARCINOMA; SYMPTOM; TERATOGENICITY; TUMOR BIOPSY; WEIGHT GAIN;

ADENOCARCINOMA; ANIMALS; ASCITES; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TIME FACTORS;

EID: 70350616220     PISSN: 02564947     EISSN: 13199226     Source Type: Journal    
DOI: 10.4103/0256-4947.55167     Document Type: Review

References (55)

1. Parsons SL, Watson SA, Steele RJ. Malignant ascites. Br J Surg. 1996;83:6-14.
2. Runyon BA. Care of patients with ascites. N Engl J Med. 1994;330:337-342.
3. Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatol. 1988;8:1104-1109.
4. Kashani A, Landaverde C, Medici V, Rossaro L. Fluid retention in cirrhosis: pathophysiology and management. QJM. 2008;101:71-85. (Pubitemid 351234707)
5. Garrison RN, Kaelin LD, Galloway RH, Heuser LS. Malignant ascites. Clinical and experimental observations. Ann Surg. 1986;203:644-651.
6. Parsons SL, Lang MW, Steele RJ. Malignant ascites: a 2-year review from a teaching hospital. Eur J Surg Oncol. 1996;22:237-239.
7. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, Angeli P, Porayko M, Moreau R, Garcia- Tsao G, Jimenez W, Planas R, Arroyo V. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatol. 2003 Jul;38(1):258-266
8. Arroyo V, Gines P, Gerbes AL. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatol. 1996;23:164-176.
9. Salerno F, Angeli P, Bernardi M, Laffi G, Riggio O, Salvagnini M. Clinical practice guidelines for the management of cirrhotic patients with ascites. Committee on Ascites of the Italian Association for the Study of the Liver. Ital J Gastroenterol Hepatol. 1999 Oct;31(7):626-634
10. Aslam N, Marino CR. Malignant ascites: new concepts in pathophysiology, diagnosis, and management. Arch Intern Med. 2001 Dec 10- 24;161(22):2733-2737
11. Siddiqui RA, Kochhar R, Singh V, Rajwanshi A, Goenka MK, Mehta SK. Evaluation of fibronectin as a marker of malignant ascites. J Gastroenterol Hepatol. 1992 Mar-Apr;7(2):161-164
12. Aslam N, Marino CR. Malignant ascites: new concepts in pathophysiology, diagnosis, and management. Arch Intern Med. 2001;161:2733-2737. (Pubitemid 33134851)
13. Kohn EC, Travers LA, Kassis J, Broome U, Klominek J. Malignant effusion are sources of fibronectin and other promigratory and proinvasive components. Diagn Cytopathol. 2005 Nov;33(5):300-308
14. Buckman R, De Angelis C, Shaw P, Covens A, Osborne R, Kerr I, Reed R, Michaels H, Woo M, Reilly R, et al. Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecol Oncol. 1992 Oct;47(1):102-109
15. Mosdell KW, Visconti JA. Emerging indications for octreotide therapy, Part 1. Am J Hosp Pharm. 1994;51:1184-1192. (Pubitemid 24144931)
16. Easson AM, Bezjak A, Ross S, Wright JG. The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites. Ann Surg Oncol. 2007;14:2348-2357. (Pubitemid 47174909)
17. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med. 2004;350:1646-1654.
18. Lee CW, Bociek G, Faught W. A survey of practice in management of malignant ascites. J Pain Symptom Manage. 1998;16:96-101. (Pubitemid 28400159)
19. Pockros PJ, Esrason KT, Nguyen C, Duque J, Woods S. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterol. 1992 Oct;103(4):1302-1306
20. Greenway B, Johnson PJ, Williams R. Control of malignant ascites with spironolactone. Br J Surg. 1982;69:441-442.
21. Gotlieb WH, Feldman B, Feldman-Moran O, Zmira N, Kreizer D, Segal Y, Elran E, Ben-Baruch G. Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer. Gynecol Oncol. 1998 Dec;71(3):381-385
22. Appelqvist P, Silvo J, Salmela L, Kostiainen S. On the treatment and prognosis of malignant ascites: is the survival time determined when the abdominal paracentesis is needed? J Surg Oncol. 1982;20:238-242.
23. Fischer DS. Abdominal paracentesis for malignant ascites. Arch Intern Med. 1979;139:235.
24. Parsons SL, Watson SA, Steele RJ. Malignant ascites. Br J Surg. 1996;83:6-14.
25. Kaushik N, Khalid A, Brody D, McGrath K. EUS-guided paracentesis for the diagnosis of malignant ascites. Gastrointest Endosc. 2006;64:908-913. (Pubitemid 44820060)
26. Kao HW, Rakov NE, Savage E, Reynolds TB. The effect of large volume paracentesis on plasma volume - a cause of hypovolemia? Hepatol. 1985;5:403-407.
27. Kellerman PS, Linas SL. Large-volume paracentesis in treatment of ascites. Ann Intern Med. 1990;112:889-891.
28. Reynolds TB. Renaissance of paracentesis in the treatment of ascites. Adv Intern Med. 1990;35:365-373.
29. Stephenson J, Gilbert J. The development of clinical guidelines on paracentesis for ascites related to malignancy. Palliat Med. 2002;16:213-218. (Pubitemid 34537663)
30. McNamara P. Paracentesis - an effective method of symptom control in the palliative care setting? Palliat Med. 2000;14:62-64.
31. Bar-Sela G, Goldberg H, Beck D, Amit A, Kuten A. Reducing malignant ascites accumulation by repeated intraperitoneal administrations of a Viscum album extract. Anticancer Res. 2006 Jan- Feb;26(1B):709-713
32. LeVeen HH, Picone VA Jr, Diaz C, Christoudias G, Slade W, Norstrand I. A simplified correction of subclavian steal syndrome. Surg. 1974 Feb;75(2):299-304.
33. Lund RH, Newkirk JB. Peritoneovenous shunting for surgical management of ascities. Contemp Surg. 1979;31-45.
34. Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer. 2006;42:589-597. (Pubitemid 43343680)
35. Souter RG, Wells C, Tarin D, Kettlewell MG. Surgical and pathologic complications associated with peritoneovenous shunts in management of malignant ascites. Cancer. 1985;55:1973-1978. (Pubitemid 15116956)
36. Tarin D, Price JE, Kettlewell MG, Souter RG, Vass AC, Crossley B. Clinicopathological observations on metastasis in man studied in patients treated with peritoneovenous shunts. Br Med J. (Clin Res Ed) 1984 Mar 10;288(6419):749-751 (Pubitemid 14117952)
37. Schumacher DL, Saclarides TJ, Staren ED. Peritoneovenous shunts for palliation of the patient with malignant ascites. Ann Surg Oncol. 1994;1:378-381.
38. Gough IR. Control of malignant ascites by peritoneovenous shunting. Cancer. 1984;54:2226-2230. (Pubitemid 15210809)
39. Souter RG, Tarin D, Kettlewell MG. Peritoneovenous shunts in the management of malignant ascites. Br J Surg. 1983;70:478-481.
40. Wickremesekera SK, Stubbs RS. Peritoneovenous shunting for malignant ascites. N Z Med J. 1997;110:33-35.
41. Murphy M, Rossi M. Managing ascities via Tenckhoff catheter. Medsurg Nurs. 1995 Dec;4(6):468-471
42. Mamada Y, Yoshida H, Taniai N, Bandou K, Shimizu T, Kakinuma D, Mizuguchi Y, Ishikawa Y, Akimaru K, Tajiri T. Peritoneovenous shunts for palliation of malignant ascites. J Nippon Med Sch. 2007 Oct;74(5):355-358 (Pubitemid 47523079)
43. Seike M, Maetani I, Sakai Y. Treatment of malignant ascites in patients with advanced cancer: peritoneovenous shunt versus paracentesis. J Gastroenterol Hepatol. 2007;22:2161-2166. (Pubitemid 350145620)
44. Revised grading system of the Scottish Intercollegiate Guidelines Network (SIGN) www.sign. ac.uk/guidelines/fulltext/50/index.html.
45. Stuart GC, Nation JG, Snider DD, Thunberg P. Intraperitoneal interferon in the management of malignant ascites. Cancer. 1993;71:2027-2030. (Pubitemid 23068552)
46. Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady J,Greene T, Ettinger LM, Lagasse LD, et al. Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancer. Cancer Treat Rev. 1985 Dec;12 Suppl B:23-32.
47. Einhorn N, Cantell K, Einhorn S, Strander H. Human leukocyte interferon therapy for advanced ovarian carcinoma. Am J Clin Oncol. 1982;5:167-172.
48. Räth U, Kaufmann M, Schmid H, Hofmann J, Wiedenmann B, Kist A, Kempeni J, Schlick E, Bastert G, Kommerell B, et al. Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. Eur J Cancer. 1991;27(2):121-125
49. Yamaguchi Y, Satoh Y, Miyahara E, Noma K, Funakoshi M, Takashima I, Sawamura A, Toge T. Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients. Anticancer Res. 1995 Sep-Oct;15(5B):2201-2206
50. Xu L, Yoneda J, Herrera C, Wood J, Killion JJ, Fidler IJ. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol. 2000 Mar;16(3):445-454 (Pubitemid 30225181)
51. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol. 1998;153:1249-1256. (Pubitemid 28465848)
52. Beattie GJ, Smyth JF. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res. 1998;4:1899-1902.
53. Low JA, Johnson MD, Bone EA, Dickson RB. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin Cancer Res. 1996;2:1207-1214.
54. Buckman R, De Angelis C, Shaw P, Covens A, Osborne R, Kerr I, Reed R, Michaels H, Woo M, Reilly R, et al. Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecol Oncol. 1992 Oct;47(1):102-109
55. Cairns W, Malone R. Octreotide as an agent for the relief of malignant ascites in palliative care patients. Palliat Med. 1999;13:429-430. (Pubitemid 29488260)